3 Biotech Stocks That Could Rocket Higher
Over the past year, these small-cap drugmakers have done well by their shareholders, and more big catalysts could be coming.
Over the past year, these small-cap drugmakers have done well by their shareholders, and more big catalysts could be coming.
These companies pay hefty dividends and have big capital appreciation potential.
Which of these two high-growth chipmakers deserves your money?
To continue, please click the box below to let us know you’re not a robot. Click here to view the
© Reuters Hospitality bosses say there could be a ‘summer of venue closures’ unless action is taken over the so-called
Well, the honorary wings carry no legal significance and no privileges anyway, and both the billionaires’ companies can bequeath…
A restaurant employee in Phoenix, Arizona, told CNN Business that staff including hostesses and dishwashers were quitting mid-shift…
Jazz Pharma is not the most popular drugmaker, but it is definitely worth a second look.
Yes, but it often doesn’t have much to do with revenue.
These fundamentally strong stocks are about to get even more attractive in the second half of 2021.